Vertex Pharmaceuticals Inc., adjustment to net income

US$ in thousands

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income (as reported)	3,619,600)	3,322,000)	2,342,100)	2,711,647)	1,176,810)
Add: Unrealized holding gains (losses) on marketable securities, net of tax	9,700)	400)	(800)	(169)	1,039)
Net income (adjusted)	3,629,300)	3,322,400)	2,341,300)	2,711,478)	1,177,849)

Download chart

Vertex Pharmaceuticals Inc., adjusted profitability ratios

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Profit Margin
Reported net profit margin	36.68%	37.20%	30.92%	43.70%	28.27%
Adjusted net profit margin	36.77%	37.20%	30.91%	43.69%	28.29%
Return on Equity (ROE)
Reported ROE	20.59%	23.88%	23.19%	31.22%	19.34%
Adjusted ROE	20.64%	23.88%	23.18%	31.21%	19.36%
Return on Assets (ROA)
Reported ROA	15.92%	18.30%	17.44%	23.07%	14.15%
Adjusted ROA	15.97%	18.30%	17.43%	23.07%	14.16%

Profitability ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by revenue.	Vertex Pharmaceuticals Inc. adjusted net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by shareholders’ equity.	Vertex Pharmaceuticals Inc. adjusted ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by total assets.	Vertex Pharmaceuticals Inc. adjusted ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.

Download chart

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Selected Financial Data (US$ in thousands)
Net income	3,619,600)	3,322,000)	2,342,100)	2,711,647)	1,176,810)
Revenues	9,869,200)	8,930,700)	7,574,400)	6,205,683)	4,162,821)
Profitability Ratio
Net profit margin¹	36.68%	37.20%	30.92%	43.70%	28.27%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income	3,629,300)	3,322,400)	2,341,300)	2,711,478)	1,177,849)
Revenues	9,869,200)	8,930,700)	7,574,400)	6,205,683)	4,162,821)
Profitability Ratio
Adjusted net profit margin²	36.77%	37.20%	30.91%	43.69%	28.29%

2023 Calculations

¹ Net profit margin = 100 × Net income ÷ Revenues
= 100 × 3,619,600 ÷ 9,869,200 = 36.68%

² Adjusted net profit margin = 100 × Adjusted net income ÷ Revenues
= 100 × 3,629,300 ÷ 9,869,200 = 36.77%

Download chart

Profitability ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by revenue.	Vertex Pharmaceuticals Inc. adjusted net profit margin ratio improved from 2021 to 2022 but then slightly deteriorated from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Selected Financial Data (US$ in thousands)
Net income	3,619,600)	3,322,000)	2,342,100)	2,711,647)	1,176,810)
Shareholders’ equity	17,580,400)	13,912,700)	10,100,000)	8,686,815)	6,085,244)
Profitability Ratio
ROE¹	20.59%	23.88%	23.19%	31.22%	19.34%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income	3,629,300)	3,322,400)	2,341,300)	2,711,478)	1,177,849)
Shareholders’ equity	17,580,400)	13,912,700)	10,100,000)	8,686,815)	6,085,244)
Profitability Ratio
Adjusted ROE²	20.64%	23.88%	23.18%	31.21%	19.36%

2023 Calculations

¹ ROE = 100 × Net income ÷ Shareholders’ equity
= 100 × 3,619,600 ÷ 17,580,400 = 20.59%

² Adjusted ROE = 100 × Adjusted net income ÷ Shareholders’ equity
= 100 × 3,629,300 ÷ 17,580,400 = 20.64%

Download chart

Profitability ratio	Description	The company
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by shareholders’ equity.	Vertex Pharmaceuticals Inc. adjusted ROE improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Selected Financial Data (US$ in thousands)
Net income	3,619,600)	3,322,000)	2,342,100)	2,711,647)	1,176,810)
Total assets	22,730,200)	18,150,900)	13,432,500)	11,751,808)	8,318,465)
Profitability Ratio
ROA¹	15.92%	18.30%	17.44%	23.07%	14.15%
Adjusted: Mark to Market Available-for-sale Securities
Selected Financial Data (US$ in thousands)
Adjusted net income	3,629,300)	3,322,400)	2,341,300)	2,711,478)	1,177,849)
Total assets	22,730,200)	18,150,900)	13,432,500)	11,751,808)	8,318,465)
Profitability Ratio
Adjusted ROA²	15.97%	18.30%	17.43%	23.07%	14.16%

2023 Calculations

¹ ROA = 100 × Net income ÷ Total assets
= 100 × 3,619,600 ÷ 22,730,200 = 15.92%

² Adjusted ROA = 100 × Adjusted net income ÷ Total assets
= 100 × 3,629,300 ÷ 22,730,200 = 15.97%

Download chart

Profitability ratio	Description	The company
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by total assets.	Vertex Pharmaceuticals Inc. adjusted ROA improved from 2021 to 2022 but then deteriorated significantly from 2022 to 2023.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Analysis of Investments